Fluconazole氟康唑,86386-73-4

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Fluconazole

CAS No. : 86386-73-4

MCE 国际站：Fluconazole

产品活性：Fluconazole (UK-49858) 是一种三唑类抗真菌剂 (antifungal)，对多种真菌具有优异的活性，尤其对Candida albicans，Fluconazole 抑制C. albicans 和 Candida kefyr 的 IC₉₉ 为 0.20 μg/mL 至 0.39 μg/mL。

研究领域：Anti-infection

作用靶点：Fungal  |  Antibiotic  |  Bacterial

In Vitro: Fluconazole inhibits 4 species ofAspergillus fumigatus with the IC₅₀s of 23.9-43.5 μg/mL. Fluconazole (0.20 μg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of C. albicans in a medium supplemented with serum.
Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to Candida, Cryptococcus. The MIC₉₀ is highest for C. krusei (MIC ≥ 64 μg/mL) and C. glabrata (MIC, 32 μg/mL) and is ≤2 μg/mL for C. albicans (0.5 μg/mL), C. parapsilosis (2 μg/mL), C. tropicalis (2 μg/mL), C. lusitaniae (2 μg/mL), and C. kefyr (0.5 μg/mL).
Fluconazole (0.1-50.0 μg/mL) damages the fungal cells and reduces their viability.

In Vivo: Fluconazole ( 0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis. ?Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p. administration.The terminal half-life does not change with the dose of fluconazole administered.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Antifungal Compound Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Tumorigenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Mitochondrial Toxicity Compound Library  |  Ferrostatin-1  |  Rapamycin  |  Cycloheximide  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Puromycin dihydrochloride  |  Dimethyl sulfoxide  |  Staurosporine  |  Actinomycin D  |  G-418 disulfate  |  Etoposide  |  5-Azacytidine  |  Cyclosporin A  |  Nigericin sodium salt  |  Brefeldin A  |  Estradiol  |  CCCP  |  Ionomycin  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Bleomycin sulfate  |  Mitomycin C  |  Everolimus  |  Doxycycline hyclate  |  Tacrolimus  |  Methotrexate

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds